Dose dependent effects of platelet derived chondroitinsulfate A on the binding of CCL5 to endothelial cells
2008

Effects of Chondroitinsulfate A on CCL5 Binding to Endothelial Cells

publication Evidence: moderate

Author Information

Author(s): Christian Weingart, Peter J. Nelson, Bernhard K. Krämer, Matthias Mack

Primary Institution: University of Regensburg

Hypothesis

How do platelet-derived glycosaminoglycans affect the binding of CCL5 to endothelial cells?

Conclusion

Chondroitinsulfate A from platelets enhances the binding of CCL5 to endothelial cells in a dose-dependent manner.

Supporting Evidence

  • Undiluted serum decreases CCL5 binding to endothelial cells.
  • Lower concentrations of serum enhance CCL5 presentation on endothelial cells.
  • Chondroitinsulfate A mediates enhanced CCL5 presentation.
  • Chondroitinsulfate B/C block CCL5 binding even at low concentrations.
  • CCL5-CSA complexes enhance receptor internalization.

Takeaway

When platelets are activated, they release a substance called chondroitinsulfate A that helps a protein called CCL5 stick better to blood vessel cells, which is important for helping white blood cells move to where they are needed.

Methodology

The study analyzed the effects of different concentrations of serum and chondroitinsulfate on CCL5 binding to human microvascular endothelial cells using flow cytometry.

Limitations

The study used high concentrations of serum and glycosaminoglycans that may not reflect in vivo conditions.

Participant Demographics

Healthy human individuals provided serum and plasma samples.

Statistical Information

P-Value

p = 0.03

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2172-9-72

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication